Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | KDM6B | O15054 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 3/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.32 |
| ▸ | KDM3B | Q7LBC6 | 3/20 | 0.32 |
| ▸ | HIF1AN | Q9NWT6 | 3/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22349659 | 0.90 | ALDH1A1 (0.33) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL22797115 | 0.88 | KDM6B (0.34) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL18526389 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL22399904 | 0.74 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL22326777 | 0.70 | ALDH1A1 (0.39) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL24117695 | 0.70 | TLR7 (0.36) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL18520816 | 0.68 | ALDH1A1 (0.42) | ADORA2AALDH1A1 | |
| SCHEMBL22547338 | 0.68 | ALDH1A1 (0.39) | ADORA2AALDH1A1 | |
| SCHEMBL24633433 | 0.67 | TLR7 (0.33) | ADORA2AADORA2B | |
| SCHEMBL24235860 | 0.66 | ADA (0.39) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | PDE4A 149/4885ADORA2A 161/4885PDE4B 159/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | PDE4A 149/4885ADORA2A 161/4885PDE4B 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.